Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.
Michelle Y ZhangMegan OthusCarole ShawKelda G SchonhoffAnna B HalpernJacob AppelbaumPaul C HendrieRoland Bruno WalterElihu H EsteyMary-Elizabeth M PercivalPublished in: Leukemia & lymphoma (2023)
Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients with AML or other high-grade myeloid neoplasms. Prior HMA therapy was significantly associated with a lower overall survival (OS) as compared to a reference group of patients with secondary disease without prior HMA therapy (median 7.2 vs 13.1 months). In patients with prior HMA therapy, high intensity induction was associated with a non-significant trend toward longer OS (median 8.2 vs 4.8 months) and decreased rates of treatment failure (39% vs 64%). These results redemonstrate poor outcomes in patients with prior HMA and suggest possible benefit of high intensity induction that should be evaluated in future studies.
Keyphrases
- high intensity
- acute myeloid leukemia
- poor prognosis
- resistance training
- allogeneic hematopoietic stem cell transplantation
- high grade
- long non coding rna
- type diabetes
- squamous cell carcinoma
- radiation therapy
- metabolic syndrome
- bone marrow
- dendritic cells
- immune response
- current status
- combination therapy
- cell therapy
- glycemic control